NCT04194671
|
Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury |
Phase 1/2 |
80 participants |
Umbilical cord |
Progression of renal function within 28 days after receiving MSC |
China |
Not yet recruiting |
NCT01275612
|
Mesenchymal Stem Cells in Cisplatin-Induced Acute Renal Failure in Patients with Solid Organ Cancers |
Phase 1 |
0 participants |
Bone marrow |
The rate of renal function loss up to 15 days postcisplatin infusion |
Italy |
Withdrawn |
NCT03015623
|
A Study of Cell Therapy for Subjects with Acute Kidney Injury Who are Receiving Continuous Renal Replacement Therapy |
Phase 1/2 |
24 participants |
Unclear |
Outcomes out to day 28 and serious adverse events through day 180 |
United States |
Recruiting |
NCT01602328
|
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects (ACT-AKI) |
Phase 2 |
156 participants |
Bone marrow |
Time to kidney recovery |
United States |
Terminated |
NCT00733876
|
Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury following Cardiac Surgery |
Phase 1 |
15 participants |
Unclear |
MSC-specific adverse or serious adverse events |
United States |
Completed |
NCT02563366
|
Effect of BM-MSCs on Early Graft Function Recovery after DCD Kidney Transplant |
Phase 1/2 |
120 participants |
Bone marrow |
Estimated glomerular filtration rate at one month posttransplant |
China |
Unknown |
NCT02561767
|
Effect of BM-MSCs in DCD Kidney Transplantation |
Phase 1/2 |
120 participants |
Bone marrow |
Estimated glomerular filtration rate at one month posttransplant |
China |
Unknown |